ALKS
Alkermes plc.
Next earnings Jul 27, 2026 · consensus $-0.02 EPS, $467M rev
Last earnings +6.1% on 2026-05-05
$55.08
▲ +4.26%$55.08▲ +88.24%
over 1Y
L $26.13EODHDH $55.08
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.3%
1W+19.7%
1M+44.6%
3M+87.4%
YTD+94.9%
1Y+88.2%
Hold
Conviction
Horizon
Medium (3–12mo)
12-mo target
$•••
Street · 23 analysts
Buy
Profitable CNS pharma with growing product sales but fading royalties; Avadel/LUMRYZ adds narcolepsy upside against looming VIVITROL generics.
Revenue (FY2025) $1.48B · FY2025
The read
Middling fundamentals and a rich price (~78% above fair value) leave little margin of safety — a wait-and-see.
Alkermes is a profitable specialty pharmaceutical company built around proprietary CNS products — ARISTADA/ARISTADA INITIO, LYBALVI and VIVITROL — plus manufacturing and royalty revenue from licensee products (long-acting INVEGA, VUMERITY). FY2025 looks weak on the surface: revenue fell 5.2% to $1.48B, operating income dropped 39.6% to $254M, and net income fell 34.2% to $242M (diluted EPS $1.43, -34.1%). But the composition matters: proprietary product sales actually grew $101.1M, with LYBALVI net sales up $66.7M to $346.7M on a 19% unit increase, VIVITROL and ARISTADA both rising modestly. The earnings decline was driven instead by a $182.8M drop in higher-margin manufacturing/royalty revenue (and the Athlone facility sale) and a 32.1% jump in R&D to $324M — i.e., a mix shift and reinvestment, not commercial-franchise failure.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.17B | $1.11B | $1.66B | $1.56B | $1.48B |
| Gross profit | — | — | — | — | — |
| Operating income | $97.7M | -$6.09M | $414M | $421M | $254M |
| Net income | -$48.2M | -$158M | $356M | $367M | $242M |
| Diluted EPS | -$0.29 | -$0.97 | $2.10 | $2.17 | $1.43 |
| Net margin | -4.1% | -14.2% | 21.4% | 23.6% | 16.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$9.08B
EV / EBITDA32.3
EV / Sales6.2
EV / FCF18.9
P / FCF19.1
PEG (trailing)—
Earnings yield2.6%
FCF yield5.2%
Quality & risk
ROIC (est.)9.5%
Free cash flow$480M
Total debt$291M
Net cash$97.8M
Altman Z-Score9.43 safe
Piotroski F-Score5/8
Capital returns
Buyback yield2.2%
Dividend yield (est.)—
Shareholder yield2.2%
Shares Δ YoY+2.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-152026-06-15open ↗4Period ending 2026-06-122026-06-12open ↗144Filing2026-06-12open ↗4Period ending 2026-06-042026-06-04open ↗144Filing2026-06-04open ↗4Period ending 2026-06-012026-06-01open ↗144Filing2026-06-01open ↗4Period ending 2026-05-292026-05-29open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗
Frequently asked
- Is Alkermes plc. (ALKS) a buy?
- ALKS currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Profitable CNS pharma with growing product sales but fading royalties; Avadel/LUMRYZ adds narcolepsy upside against looming VIVITROL generics.
- What is ALKS's fair value?
- A Modified-Graham model based on ALKS's SEC fundamentals estimates a fair value of about $12.16. It is an estimate from reported earnings, not a price target.
- Is ALKS overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, ALKS currently appears overvalued relative to its SEC-grounded earnings power.
- What is Alkermes plc.'s quality score?
- ALKS scores 60.43137254901961/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001520262, latest 10-Q filed 2026-05-05) · EODHD · analysis by claude-code · as of 6/21/2026, 8:54:37 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.